What Will Happen When Rebates Go Away? Look At Authorized Generics
Executive Summary
Recent launches by Lilly, Amgen and Gilead suggest list prices may decrease with the HHS proposal to disrupt the rebate system, but not as low as current net prices after rebates, according to pharmacy benefit experts.
You may also be interested in...
HHS Importation Plan Builds On Use Of Authorized Generics To Lower US List Prices
Plan envisions manufacturers, acting under FDA guidance, will import their own drugs and introduce them in the US under a new national drug code at a lower list price.
One More Score: CBO Projects HHS Rebate Proposal Would Boost Part D Spending $170bn
HHS downplays latest attempt to predict “complex behavior changes to a broken system.”
Same Drug, Two Versions And Prices, This Time For Lilly's Humalog
Lilly will launch an authorized generic version of Humalog at a 50% discount to the brand to assist patients without insurance or a high deductible, who don't benefit from rebates.